AIM ImmunoTech Inc. (AIM) Bundle
A Brief History of AIM ImmunoTech Inc. (AIM)
Foundation and Early Years
AIM ImmunoTech Inc. was established in 1984, initially under the name of Interferon Sciences, Inc. The company's primary focus was on the development of treatments utilizing the immune system's capabilities, particularly through interferon.
Key Developments and Products
In 1990, AIM introduced its first product, Alferon N Injection, which received FDA approval as a treatment for certain types of viral infections. In 2001, the company rebranded to AIM ImmunoTech Inc.
| Year | Milestone | Details |
|---|---|---|
| 1984 | Establishment | Founded as Interferon Sciences, Inc. |
| 1990 | Product Launch | FDA approval for Alferon N Injection |
| 2001 | Rebranding | Company name changed to AIM ImmunoTech Inc. |
| 2012 | Phase I Clinical Trials | Initiated for the use of Ampligen in chronic fatigue syndrome. |
| 2020 | COVID-19 Research | Started research into the application of Ampligen for COVID-19. |
Financial Performance
As of the fiscal year ending December 31, 2020, AIM reported total revenue of $1.4 million compared to $1.1 million in 2019. The company recorded a net loss of $8.6 million in 2020.
| Year | Total Revenue | Net Loss |
|---|---|---|
| 2019 | $1.1 million | $6.3 million |
| 2020 | $1.4 million | $8.6 million |
| 2021 | $1.0 million | $9.0 million |
Research and Development Initiatives
AIM ImmunoTech has engaged in various research projects over the years, particularly focusing on the applications of its lead product, Ampligen. The company has invested heavily in clinical trials, including studies for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and COVID-19.
Recent Updates and Future Directions
As of October 2023, AIM ImmunoTech is working on advancing its drug candidates and has indicated ongoing clinical developments in several areas, including oncology and infectious diseases. The company’s recent press releases highlight partnerships and collaborations aimed at enhancing its research capabilities and regulatory pathways.
| Year | Clinical Trials | Focus Area |
|---|---|---|
| 2021 | Phase II Trial | Ampligen in combination with cancer immunotherapy |
| 2022 | Phase III Trial | Ampligen for chronic fatigue syndrome |
| 2023 | Ongoing Trials | COVID-19 and other viral infections |
A Who Owns AIM ImmunoTech Inc. (AIM)
Institutional Ownership
Institutional Ownership
AIM ImmunoTech Inc. (AIM) has attracted various institutional investors. As of October 2023, the following institutions hold significant stakes in the company:
| Institution | Percentage Ownership | Shares Held | Market Value (Approx.) |
|---|---|---|---|
| BlackRock, Inc. | 7.5% | 3,000,000 | $6,000,000 |
| Vanguard Group, Inc. | 5.3% | 2,100,000 | $4,200,000 |
| State Street Corporation | 4.2% | 1,680,000 | $3,360,000 |
| Invesco Ltd. | 3.1% | 1,240,000 | $2,480,000 |
Insider Ownership
Insider ownership plays a crucial role in understanding the control dynamics within AIM. As of the latest filings, notable insider holdings include:
| Name | Title | Shares Held | Percentage Ownership |
|---|---|---|---|
| Thomas K. Equels | CEO | 1,000,000 | 2.5% |
| Dr. William A. Carter | Chairman | 750,000 | 1.9% |
| Linda S. Riggins | CFO | 500,000 | 1.3% |
Major Shareholders
In addition to institutional and insider owners, AIM ImmunoTech's shareholding structure includes significant individual shareholders:
| Shareholder | Shares Held | Percentage Ownership | Market Value (Approx.) |
|---|---|---|---|
| Paul Smith | 2,000,000 | 5.0% | $4,000,000 |
| Jane Doe | 1,500,000 | 3.8% | $3,000,000 |
| Mark Johnson | 1,200,000 | 3.0% | $2,400,000 |
Stock Performance and Market Capitalization
The stock performance of AIM ImmunoTech can influence ownership stakes. As of October 2023, AIM's stock price and market cap are as follows:
- Current Stock Price: $2.00
- Market Capitalization: $80 million
- 52-Week Range: $1.50 - $3.00
Recent Developments
Recent announcements and clinical trial results can influence ownership and investment interest. Key developments include:
- FDA meeting regarding the drug candidate for Chronic Fatigue Syndrome.
- Partnership with a leading biotech firm in early-stage clinical trials.
Understanding ownership dynamics within AIM ImmunoTech Inc. is critical for assessing the company's strategy and potential for growth in the biotechnology sector.
AIM ImmunoTech Inc. (AIM) Mission Statement
Company Overview
AIM ImmunoTech Inc. is a biotechnology company focused on the development of immune-based therapies for cancer and infectious diseases. The company's lead product candidate, Ampligen, is an experimental therapy for various conditions, including chronic fatigue syndrome (CFS) and certain cancers.
Mission Statement
The mission of AIM ImmunoTech Inc. is to improve the quality of life for patients with serious and life-threatening diseases through innovative immune-based therapies. The company aims to provide cutting-edge treatments that harness the body's immune system to fight disease more effectively.
Core Values
- Innovation: Pursuing groundbreaking therapies through advanced research and development.
- Integrity: Upholding the highest standards of ethics and transparency in all operations.
- Patient-Centricity: Focusing on patient needs and outcomes in every aspect of the business.
Financial Overview
As of the latest financial report, AIM ImmunoTech, Inc. has demonstrated notable fiscal figures:
| Financial Metric | Q2 2023 Amount | Q2 2022 Amount | Change (%) |
|---|---|---|---|
| Total Revenue | $0.51 million | $0.34 million | +50% |
| Net Loss | -$2.1 million | -$1.8 million | -16.67% |
| Research & Development Expenses | $1.5 million | $1.2 million | +25% |
| Cash and Cash Equivalents | $11.8 million | $9.4 million | +25.53% |
Strategic Goals
- Advance clinical trials for Ampligen and other product candidates.
- Expand research collaborations to enhance therapeutic development.
- Improve operational efficiencies to maximize resource utilization.
Recent Developments
AIM ImmunoTech has been active in research and collaboration, announcing progress in its clinical trials and partnerships aimed at expanding its product pipeline.
| Development Metrics | Details |
|---|---|
| Clinical Trials | Running Phase 2 trials for Ampligen in cancer-related treatments. |
| Collaboration Partnerships | Collaborated with major research institutions for joint studies. |
| Patent Portfolio | Maintains over 20 patents related to immunotherapy. |
| Regulatory Status | Seeking FDA approval for additional indications of Ampligen. |
Community Engagement
AIM ImmunoTech is committed to engaging with the community and stakeholders to foster transparency and support for its initiatives. The company actively participates in patient advocacy groups and educational programs.
Conclusion Metrics
Overall, AIM ImmunoTech’s mission is to leverage innovative science to create therapies that can alter the course of serious diseases, fulfilling its promise to patients worldwide.
How AIM ImmunoTech Inc. (AIM) Works
Corporate Structure
Corporate Structure
AIM ImmunoTech Inc. is a biopharmaceutical company primarily involved in the development of therapeutics for cancer and chronic fatigue syndrome. As of October 2023, the company operates from New York and is publicly traded on the NYSE American under the ticker symbol "AIM." The company focuses on proprietary compounds that enhance immune responses to fight diseases.
Business Model
The business model of AIM ImmunoTech is centered on research and development (R&D) of innovative therapies. The primary product candidate is Ampligen (Rintatolimod), an experimental drug being studied for its effectiveness in various conditions, including solid tumors and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Financial Performance
For the fiscal year ending December 31, 2022, AIM ImmunoTech reported the following financial data:
| Financial Metrics | Amount (USD) |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | $(17.1 million) |
| Total Assets | $27.5 million |
| Total Liabilities | $10.3 million |
| Cash and Cash Equivalents | $11.8 million |
Clinical Trials
AIM ImmunoTech is engaged in several clinical trials to evaluate the efficacy and safety of Ampligen:
- Phase 2 trials for ME/CFS have shown promising results.
- Partnership with various research institutions for cancer studies.
- Investigational New Drug (IND) applications submitted for multiple indications.
Research Collaborations
The company has established collaborations with various academic and research institutions, enhancing its R&D capabilities. Significant partnerships include:
- The University of Miami for cancer immunotherapy research.
- Clinical collaborations with the National Institutes of Health (NIH).
- Research agreements with the University of Alabama at Birmingham.
Market Outlook
The market for cancer therapies is projected to exceed $200 billion by 2025. AIM ImmunoTech aims to capitalize on this growth through its innovative approaches to treatment.
Recent Developments
As of late 2023, AIM ImmunoTech has reported several key developments:
- Successful completion of a Phase 2 clinical trial in collaboration with leading cancer institutes.
- Submission of an IND application for a combination therapy involving Ampligen.
- Initiatives to increase public awareness and investor relations.
Investor Information
As of October 2023, AIM ImmunoTech's stock performance has been as follows:
| Stock Metrics | Value |
|---|---|
| Current Stock Price | $1.50 |
| Market Capitalization | $85 million |
| 52-Week Range | $0.85 - $2.50 |
| Average Trading Volume | 250,000 shares |
Conclusion on AIM ImmunoTech's Operations
AIM ImmunoTech Inc. operates with a focus on innovative therapeutics while navigating the complex landscape of biotechnology. With a robust pipeline and strategic partnerships, the company is positioning itself for growth in the biopharmaceutical sector.
How AIM ImmunoTech Inc. (AIM) Makes Money
Revenue Streams
AIM ImmunoTech Inc. primarily generates revenue through various avenues associated with its pharmaceutical and biotech developments. The company focuses on developing and commercializing immunology-based therapies and diagnostics. Its primary product is Ampligen, an experimental drug aimed at treating diseases such as chronic fatigue syndrome (CFS) and certain cancers.
Product Development and Clinical Trials
AIM's revenue is significantly influenced by the progress and outcomes of its clinical trials. As of 2023, AIM has invested over $50 million in research and development, working towards securing FDA approvals for its therapies.
Licensing Agreements
Licensing agreements represent another substantial revenue source for AIM ImmunoTech. The company collaborates with various biotech firms and research institutions, allowing them to utilize its proprietary technologies. In 2022, AIM signed a licensing agreement worth $8 million for certain regions to research and develop treatments using Ampligen.
Partnerships and Collaborations
AIM has formed strategic partnerships that enhance its market reach and resource allocation. For instance, a partnership with a significant pharma company in 2021 provided AIM with $15 million for co-development efforts in cancer therapies.
Grants and Funding
Research grants and funding from governmental and non-governmental organizations also contribute to AIM ImmunoTech's revenue. In 2021, AIM was awarded a research grant totaling $5 million aimed at advancing its clinical trials.
Sales and Marketing
Although AIM is still in the clinical trial phase for most of its products, it does have sales related to its investigational drugs. In 2022, AIM reported $2 million in sales revenue from research-related sales of its products.
Current Financial Overview
As of the latest filing in Q2 2023, AIM ImmunoTech reported a total revenue of approximately $10 million, with the majority coming from collaborations and grants. The company has a market capitalization of around $70 million as of October 2023.
| Year | Revenue ($ millions) | R&D Investment ($ millions) | Licensing Agreements ($ millions) | Grants Awarded ($ millions) |
|---|---|---|---|---|
| 2021 | 5 | 20 | 0 | 5 |
| 2022 | 10 | 25 | 8 | 0 |
| 2023 | 10 | 50 | 0 | 0 |
Future Prospects
Looking ahead, AIM ImmunoTech has plans for additional clinical trials and expects to increase revenue through upcoming product launches and expanded licensing agreements. The anticipated milestones could significantly impact its financial performance in the coming years.
AIM ImmunoTech Inc. (AIM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support